Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Shares Bought by Capital Group Private Client Services Inc.

Capital Group Private Client Services Inc. boosted its stake in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 95.8% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 119,218 shares of the biotechnology company’s stock after acquiring an additional 58,335 shares during the quarter. Capital Group Private Client Services Inc.’s holdings in Sarepta Therapeutics were worth $14,496,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. Charles Schwab Investment Management Inc. increased its holdings in shares of Sarepta Therapeutics by 2.0% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 623,749 shares of the biotechnology company’s stock valued at $75,842,000 after purchasing an additional 12,000 shares in the last quarter. Proficio Capital Partners LLC purchased a new position in Sarepta Therapeutics in the fourth quarter valued at $3,829,000. Nordea Investment Management AB raised its position in shares of Sarepta Therapeutics by 19.1% in the fourth quarter. Nordea Investment Management AB now owns 67,546 shares of the biotechnology company’s stock worth $8,228,000 after acquiring an additional 10,815 shares during the period. Allspring Global Investments Holdings LLC boosted its stake in shares of Sarepta Therapeutics by 16,717.7% during the 4th quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock worth $10,602,000 after acquiring an additional 84,926 shares in the last quarter. Finally, Van ECK Associates Corp grew its position in shares of Sarepta Therapeutics by 24.4% during the 4th quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock valued at $10,315,000 after acquiring an additional 16,658 shares during the period. 86.68% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, Director Claude Nicaise sold 2,491 shares of the stock in a transaction on Wednesday, March 12th. The stock was sold at an average price of $99.64, for a total transaction of $248,203.24. Following the completion of the transaction, the director now directly owns 27,812 shares in the company, valued at approximately $2,771,187.68. This represents a 8.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 7.70% of the stock is owned by insiders.

Sarepta Therapeutics Stock Performance

Sarepta Therapeutics stock opened at $53.79 on Friday. The stock has a market cap of $5.22 billion, a price-to-earnings ratio of 43.03 and a beta of 0.93. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The firm has a 50 day simple moving average of $82.21 and a 200-day simple moving average of $107.88. Sarepta Therapeutics, Inc. has a 1-year low of $48.01 and a 1-year high of $173.25.

Analysts Set New Price Targets

A number of equities analysts have issued reports on SRPT shares. Scotiabank lowered their price target on Sarepta Therapeutics from $105.00 to $80.00 and set a “sector perform” rating on the stock in a research report on Thursday, March 20th. Cantor Fitzgerald reissued an “overweight” rating and issued a $163.00 price target on shares of Sarepta Therapeutics in a research note on Tuesday, March 18th. HC Wainwright restated a “neutral” rating and set a $75.00 price objective on shares of Sarepta Therapeutics in a research report on Wednesday. Morgan Stanley decreased their price objective on shares of Sarepta Therapeutics from $196.00 to $182.00 and set an “overweight” rating on the stock in a report on Friday, April 11th. Finally, Deutsche Bank Aktiengesellschaft cut their target price on shares of Sarepta Therapeutics from $124.00 to $99.00 and set a “hold” rating for the company in a research note on Wednesday, March 19th. Six investment analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $161.83.

About Sarepta Therapeutics

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.